Ausdal Financial Partners Inc. boosted its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,599 shares of the company’s stock after purchasing an additional 542 shares during the quarter. Ausdal Financial Partners Inc.’s holdings in Johnson & Johnson were worth $2,226,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. DORCHESTER WEALTH MANAGEMENT Co lifted its position in shares of Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after acquiring an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P lifted its position in shares of Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after acquiring an additional 82,429 shares during the period. AMI Investment Management Inc. lifted its position in shares of Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after buying an additional 1,475 shares during the last quarter. Equitable Holdings Inc. lifted its position in shares of Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after buying an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd lifted its position in shares of Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after buying an additional 20,528 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
JNJ has been the subject of several recent analyst reports. Morgan Stanley upped their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 19th. StockNews.com initiated coverage on Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating for the company. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Guggenheim started coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective for the company. Finally, Piper Sandler lowered their target price on Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $173.00.
Johnson & Johnson Trading Down 0.1 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a return on equity of 35.53% and a net margin of 13.22%. The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.67 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 2.91%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is currently 94.56%.
Insider Buying and Selling
In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.20% of the stock is currently owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Insiders Drive Volatility For Keurig Dr Pepper
- After a 40% Drop, Analysts Remain Bullish on Impinj
- Visa Charges Higher After Better-Than-Expected Q2 Report
- onsemi Puts A Bottom in Chip Stocks, Heads For New Highs
- Can Teladoc Stock Be Resuscitated?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
